PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50121C00073 — EO14042 LETTER CONTRACT ADD FAR 52.223-99 ENSURING ADEQUATE COVID-19 SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS (OCT 2021…

EO14042 LETTER CONTRACT ADD FAR 52.223-99 ENSURING ADEQUATE COVID-19 SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS (OCT 2021… is a federal NONE award for Department of Health and Human Services (HHS) held by ELUSYS THERAPEUTICS, INC.. Estimated value $80.9M ($30.0M obligated). Current period of performance ends Sep 14, 2024. Last award drew 1 bidder. Place of performance: PARSIPPANY, NJ. Related solicitation 6/28/2021.

$80.9M
Estimated Value
$30.0M
Obligated
Sep 14, 2024
PoP End / Expires
1
Bidders (last award)
More in SCOUT — score this to your firm →See related expiring contracts →

Analysis

Public

ELUSYS THERAPEUTICS, INC. holds $113.9M across 5 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. PoP ended Sep 14, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Contract facts

NONE
Contract number75A50121C00073
AgencyDepartment of Health and Human Services (HHS)
IncumbentELUSYS THERAPEUTICS, INC.
UEIELP1DCK8L191
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Place of performancePARSIPPANY, NJ
Related solicitation6/28/2021
PoP end (current)Sep 14, 2024
Obligated$30.0M

EO14042 LETTER CONTRACT ADD FAR 52.223-99 ENSURING ADEQUATE COVID-19 SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS (OCT 2021)(DEVIATION)

Recompete timing

Public
Past PoP end (698 days ago)

Current PoP ended Sep 14, 2024 (698 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Track recompete timing in SCOUT →

Incumbent footprint

Public record

ELUSYS THERAPEUTICS, INC.$113.9M obligated across 5 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$113.9M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Score this to your firm — $90 Pilot →

Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. 90 days · $90 · no annual contract · cancel anytime

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open ELUSYS THERAPEUTICS, INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50121C00073?

75A50121C00073 (EO14042 LETTER CONTRACT ADD FAR 52.223-99 ENSURING ADEQUATE COVID-19 SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS (OCT 2021…) is a Department of Health and Human Services (HHS) award with an estimated value of $80.9M, currently held by ELUSYS THERAPEUTICS, INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50121C00073?

ELUSYS THERAPEUTICS, INC. is the incumbent with $113.9M across 5 related awards in SCOUT’s public footprint. The current period of performance ends Sep 14, 2024.

When does 75A50121C00073 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 14, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/75A50121C00073